For the first time since its launch, ADIHEX’s 18th edition to be extended to 7 days International Fair
18.8.2020 19:07:00 EEST | Business Wire | Press release
The Higher Organizing Committee of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) have announced that the 18th edition of the event will take place over seven days from September 27 to October 3, 2021, at the Abu Dhabi National Exhibition Centre (ADNEC), under the patronage of H.H. Sheikh Hamdan bin Zayed Al Nahyan, Ruler's Representative in Al Dhafra Region and Chairman of Emirates Falconers’ Club. The exhibition will extend for the first time in its history over 7 consecutive days, in line with its development strategy turning it into a comprehensive International fair.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200818005638/en/
Photos from ADIHEX 2019 (Photo: AETOSWire)
H.E. Majed Ali Al Mansouri, Secretary-General of the Emirates Falconers’ Club and Chairman of the Higher Organizing Committee of ADIHEX, said that the kind gesture of the event’s patron, H.H. Sheikh Hamdan bin Zayed Al Nahyan, Ruler's Representative in Al Dhafra Region and Chairman of Emirates Falconers’ Club, and his directives to extend the exhibition for an entire week came as a result of the unprecedented eagerness from the event participants.
H.E. Al Mansouri explained that the extension will offer visitors and exhibitors a greater opportunity to benefit from the event to network and conclude their business deals. It will also help meet the rising aspirations of the visitors, including those interested in falconry, hunting and equestrian from around the world.
H.E. Majed Al Mansouri added that the event witnessed an impressive increase in visitor’s number reaching a total of 1.6 million from its launch to 2019 edition.
H.E. Al Mansouri reiterated that the next edition will be unique as it coincides with the UAE’s 50 years celebration of success and achievements, and the launch of the Golden Jubilee plan for the next 50 years.
The Emirates Falconers' Club has approved a strategic plan to maintain ADIHEX as the largest exhibition of its kind in the MEA region, over the coming years. The plan includes the expansion of the event’s space gradually; achieving a quantum leap in the number of local and international exhibitors and visitors.
H.E. AL Mansouri said: “while preparing for the next 50 years, The UAE has made unique achievements in various fields over the past decades; and has managed to occupy leading positions regionally and globally in the field of government efficiency and economic competitiveness while preserving its heritage at the same time.
The next edition of ADIHEX will be held under the theme ‘Sustainability and Heritage… A Reborn Aspiration’, which reflects the efforts of Abu Dhabi and the world to promote environmental and sustainable hunting, heritage sports and related industries.
ADIHEX provides its participants and visitors with a comprehensive offering within its 11 sectors: veterinary products and services, hunting guns, media, outdoor leisure vehicles and equipment, hunting tourism and safari, arts and crafts, equestrian, falconry, fishing and marine sports, hunting and camping equipment and cultural heritage.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005638/en/
Contact information
Abeer Mahmoud
abeer@pyramedia.biz
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom